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What is already known about the topic? 
Data on the health state utility values of Multiple Sclerosis (MS) health states have been described as 
sparse or of questionable methodological quality. This has led to uncertainty in assessing the 
effectiveness and cost-effectiveness of treatments for MS, and has hampered decision-making 
regarding the funding of MS interventions.  
 
What does the paper add to existing knowledge? 
The research reported here provides new, detailed, empirical MS EQ-5D and SF-6D health state 
utility value data, based on a UK representative sample of people with MS, by a variety of key 
demographic and clinical characteristics.  
 
What insights does the paper provide for informing health care-related decision making? 
This data can be used to help offer decision-makers more precise estimates of the effectiveness and 
cost-effectiveness of treatments for MS.  
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Abstract 
 
Objectives: To estimate health state utility values (HSUVs) for Multiple Sclerosis (MS) by key 
demographic and clinical characteristics.  
Methods: Data from a UK prospective, longitudinal, cohort study of people with MS were used for 
analysis. Patient-reported outcomes on the EQ-5D and the SF-36 (SF-6D) were used to estimate 
HSUVs by age, gender, MS type, time since diagnosis, disease severity (Expanded Disability Status 
Scale, EDSS), and relapse characteristics. 
Results: The cohort (n=1,441) (11,778 returned questionnaires) was representative of the UK MS 
population. Data indicated that primary and secondary progressive MS were associated with lower 
HSUVs than relapsing-remitting MS, and HSUVs decreased by disease severity. This was particularly 
apparent for the EQ-5D, with mean estimates ranging from 0.846 to 0.025 for EDSS states 0 to 8, 
compared to mean SF-6D estimates ranging from 0.702 to 0.529. Experiencing a relapse in the 
previous six months had a significant impact on HSUVs, with mean decrements of 0.076 for the EQ-
5D and 0.052 for the SF-6D. 
Conclusions: These findings demonstrate the negative impact of MS on health-related quality-of-life, 
especially as the condition progresses, and indicate the substantial influence of varying features of 
relapses on HSUVs. This is the first report of SF-6D values for a UK MS population and the first time 
that EQ-5D data have been presented in such detail for people with MS. The representative nature of 
the sample means that this data can be used to offer decision-makers more precise estimates of the 
effectiveness and cost-effectiveness of MS treatments.  
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Introduction 
 
Multiple Sclerosis (MS) is a chronic, disabling neurological disorder which can affect any system of 
the body. It is one of the commonest global causes of neurological disability in young and middle-
aged adults (1) (2), with a worldwide prevalence of approximately 33 per 100,000 population (3). 
Approximately 85% of people when first diagnosed with MS are diagnosed with relapsing-remitting 
MS (RRMS) (4). Their disease course is characterised by episodes when they are well and episodes, 
known as relapses, when they experience an acute exacerbation of existing symptoms or new 
symptoms (5) (6). MS and the relapses experienced have a profound impact on health-related quality 
of life (7) (3), commensurate with congestive heart failure, chronic obstructive pulmonary disease, 
Type II diabetes, and having experienced an acute myocardial infarction in the previous year (8).  
 
One of the ways in which health-related quality of life can be assessed is by considering the health 
state utility values (HSUVs) of different health states experienced by individuals with the condition of 
interest. HSUVs are used to assign a value to health states that may be experienced. These values 
are on a scale where one represents, or is equivalent to, full health and zero is considered equivalent 
to being dead. Values can also be negative, representing health states valued as worse than being 
dead (9). 
 
Such HSUVs have specific relevance to health policy and health technology assessments, as they 
comprise the ‘quality weight’ in quality-adjusted life-years (QALYs) (9) (10). QALYs are one of the key 
inputs in analyses of the effectiveness and cost-effectiveness of treatments, and are one of the main 
outcome measures used in funding decision-making, particularly in the UK, Europe, and publically 
funded health care systems (11) (12) (13) (14). HSUVs can have a major impact on results obtained 
from health technology appraisals (15) and yet, data on the HSUVs of MS health states have been 
described as sparse or of questionable methodological quality (16). Systematic reviews of the cost-
effectiveness of treatments for MS  have highlighted particular issues with the HSUVs available for 
MS (17) (18) (19) (20), and a systematic review of MS HSUVs (16) identified inconsistencies and 
marked variability in the values reported. For example, higher HSUVs have been described for 
disease severity scores indicative of poorer health status (21) (22) and HSUV losses associated with 
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MS relapse events have been reported as ranging from 0.029 (23) to 0.8 (24) (25). This has led to 
uncertainty in assessing the effectiveness and cost-effectiveness of treatments for MS (26) (19), and 
hampered decision-making regarding the funding of MS interventions (27) (28) (29). Therefore, the 
aim here was to estimate HSUVs for MS using data from a prospective, longitudinal, cohort study of 
people with MS by demographic and clinical characteristics, including valuation by disease severity 
and the characteristics of relapses.  
 
 
 
Methods 
 
 
The South West Impact of Multiple Sclerosis (SWIMS) project 
 
Data from the UK South West Impact of Multiple Sclerosis (SWIMS) project (30) were used for 
analysis. SWIMS is a longitudinal, prospective, cohort study of people with MS in Devon and Cornwall 
(South West England), with individuals followed-up six-monthly. Full details of the study methods 
have been reported elsewhere (30). Data are collected on demographics and clinical characteristics, 
and on a range of patient-reported outcome measures. SWIMS commenced recruitment in August 
2004, and data from all participants who had completed initial questionnaires at October 2012 were 
included in this analysis.  
 
The study was approved in the UK by the Cornwall and Plymouth and South Devon Research Ethics 
Committees, and written informed consent obtained from all participants.  
 
 
Measures 
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Demographic and clinical characteristics 
 
Participants reported their age and gender, the type of MS they had (aided by descriptions and 
graphical representations similar to those used by Bamer et al. (31) and Lublin et al. (32)) and the 
length of time since their diagnosis. Participant-reported data was supplemented, where available, 
with clinician-reported assessment of disease severity using the Expanded Disability Status Scale 
(EDSS) (33) scores, collected during routine clinic visits. These were matched with HSUV data if 
recorded within the same three-month window.  
 
Participants reported relapse events for the prior six months, reporting if they had experienced a 
relapse, the number experienced, their length (‘lasted about 48 hours’, ‘lasted up to 1 week’, ‘lasted 
up to 1 month’, or ‘lasted longer than 1 month’), whether they had been admitted to hospital as a 
result, and if the relapse had limited everyday activities. They were asked to give these details for up 
to four relapses in the six month period. (At recruitment, this information was reported for the previous 
12 months).  
 
 
Health state utility values 
 
Participants completed both the EQ-5D-3L (34) (35) (36) and version 2 of the SF-36 (37) from which 
the SF-6D (38) can be derived. Participants completed both instruments at baseline and, thereafter, 
one of each measure every six months. 
 
The EQ-5D-3L (34) (35) (36) is the most widely used generic preference-based measure for deriving 
HSUVs (39). It is used internationally (there are currently 141 language versions), and has become 
increasingly commonplace in clinical trials and economic evaluations in the UK, given that it is the 
measure recommended by NICE in its reference case for health technology assessment submissions 
(11). The EQ-5D-3L descriptive system has five dimensions, each of which can be assigned at three 
levels. Its dimensions are Mobility, Self-care, Usual activities, Pain/Discomfort and 
Anxiety/Depression. The levels relate to the severity of problems on each of the dimensions; 1 
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represents ‘no problems’, 2 ‘some or moderate problems, and 3 ‘extreme problems/unable’, with the 
exception of Mobility level 3 which is described as ‘confined to bed’. Participants’ responses to the 
descriptive system were assigned HSUVs based on time trade-off valuations from a representative 
sample of  members of the UK general population (40) (41). EQ-5D-3L HSUVs range from -0.594 
(equivalent to being dead) to 1 (full health).  
 
The internationally recognised SF-36, currently in its second version, includes 36 self-report questions 
regarding functional health and well-being (37). The descriptive system of the SF-6D (38) is based on 
11 items from the SF-36 and comprises six dimensions; Physical functioning, Bodily pain, Vitality, 
Social functioning, Mental health, and Role limitation. Participants respond to questions on each of 
these dimensions to indicate the severity of their health state. The dimensions have between four and 
six response levels each. Participants’ responses were assigned HSUVs based on standard gamble 
valuations by a representative sample of the UK general public (38). SF-6D HSUVs range from 0.3 to 
1 (full health).  
 
 
Data analyses 
 
The demographic and clinical characteristics of the SWIMS sample were described at recruitment, 
and were compared for representativeness with other samples of people with MS in the UK.  
 
Mean (sd) HSUVs were calculated by participants’ age, gender, type of MS (relapsing-remitting - 
RRMS, primary progressive - PPMS, secondary progressive - SPMS, benign), time since diagnosis, 
disease severity according to the EDSS, and the number and features of relapses experienced. 
 
Data management was conducted in Excel 2007 and STATA 12.1, and all data analyses were 
conducted in STATA 12.1, with data defined as panel data using the xt commands. 
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Results 
 
 
Description of the sample and data 
 
Data from 1,441 people with MS were available, comprising 11,778 completed SWIMS 
questionnaires. Respondents provided a mean (sd) of 8 (4) questionnaires, with a range from one to 
17. The demographic and clinical features of participants on recruitment to SWIMS are given in Table 
1.  
 
 
Representativeness of the sample 
 
Approximately 75% of those approached have taken part in the SWIMS study and response rates 
have been remarkably high (90% at 3.5 years follow-up (42)). The sample, at recruitment, was 
demographically comparable to other UK samples of people with MS (42) (43) (although the 
percentage of respondents reporting a diagnosis of primary progressive MS was slightly higher: 19% 
as compared to 15%) (43). For example, previous population surveys over the past 20 years have 
found mean ages of between 49.3 and 52.0 years (as compared to 50.7 years in the SWIMS sample), 
and male to female gender ratios ranging from 1:2.1 to 1:2.8 (as compared to 1:2.8 in the SWIMS 
sample) (44-50). In addition, the relapse rate in the SWIMS sample (1.1 a year) was very similar to 
those estimated in prospective evaluations of relapses (0.5 to 1 a year) (51). The demographic and 
clinical characteristics of the SWIMS participants were also comparable to those of individuals 
described in a recent paper documenting findings from a UK MS Register project. The 4,516 
respondents had a mean (sd) age of 50.7 (11.2) years, the same as the SWIMS sample, a female: 
male ratio of 2.5, and were a mean (sd) of 10.9 (8.9) years since diagnosis (43). 
 
Health state utility values (HSUVs) 
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6,066 fully completed EQ-5D questionnaires were available from 1,406 participants, and 5,964 SF-6D 
responses were provided by 1,357 participants. The mean (sd) EQ-5D value was 0.563 (0.312), and 
the mean (sd) SF-6D value 0.620 (0.122). HSUVs for both measures covered the full valuation range. 
A comparison of HSUVs for people with MS with UK norms is described in Supplement 1.  
 
 
HSUVs by MS type 
 
Table 2 presents HSUVs by type of MS. According to both the EQ-5D and the SF-6D, HSUVs were 
lower for those with PPMS and SPMS than for those with RRMS, implying that the former sub-types 
of MS have a greater impact on health-related quality of life.  
 
 
HSUVs by time since diagnosis 
 
Table 2 presents HSUVs for MS according to self-report time since diagnosis. When considering all 
types of MS, for both the EQ-5D and the SF-6D, values decrease from the point of diagnosis to 20 to 
29 years post-diagnosis, followed by a slight increase between approximately 30 and 39 years, before 
a further decline thereafter. Although not so pronounced, this pattern also holds separately for 
individuals with RRMS. The trajectory for PPMS appears similar, but with HSUVs falling at 10 to 19 
years, before improving at 20 to 29 years.  
 
 
HSUVs by disease severity according to the EDSS 
 
Table 3 presents HSUVs by EDSS scores according to MS type. These data show a broadly linear 
decrease in values from EDSS 0 to EDSS 8. This is particularly apparent with the SF-6D data. With 
the EQ-5D, there is a flattening of values at EDSS 3 and EDSS 4, and a more sharp decrease from 
EDSS 7 to EDSS 8. There is greater variability in EQ-5D values of those individuals with RRMS. Their 
values were worse than individuals with PPMS at EDSS score 3 (‘Moderate disability’), improved at 
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EDSS score 4 (‘Relatively severe disability’), dropped at EDSS 5 (‘Disability precludes full daily 
activities’), and improved at EDSS 6 (‘Assistance required to walk’). The trajectory of EQ-5D values by 
EDSS score was very similar for those who had PPMS and SPMS. 
 
 
HSUVs in relation to relapses 
 
Table 4 presents EQ-5D and SF-6D HSUVs for MS in the context of particular features of relapse 
events. These data show that experiencing a relapse in the previous six months (as compared to not 
experiencing a relapse) was associated with a decrement of 0.076 in EQ-5D value. The data also 
indicate that the number of relapses had a negative relationship with EQ-5D values. Individuals who 
experienced one relapse had a mean (sd) EQ-5D value of 0.570 (0.297), whilst those who 
experienced four relapses in the six month period had a mean (sd) EQ-5D value of 0.380 (0.377). The 
difference in EQ-5D values between those who had not experienced a relapse and those who had 
experienced four relapses was 0.23. 
 
These data also show that experiencing a relapse in the previous six months was associated with a 
mean decrement of 0.052 in SF-6D values. The number of relapses had a negative relationship with 
SF-6D values. Individuals who experienced one relapse had a mean (sd) SF-6D value of 0.607 
(0.115), whilst those who experienced four relapses in the six month period had a mean (sd) SF-6D 
value of 0.551 (0.115). The difference in SF-6D values between those who had not experienced a 
relapse and those who had experienced four relapses was 0.098. The relationship between number 
of relapses and health state value decrement for the SF-6D was much less pronounced than for the 
EQ-5D. 
 
The relationship between the length of relapses and HSUVs indicated that relapses that lasted ‘about 
48 hours’ or for ‘up to 1 week’ were associated with the lowest EQ-5D and SF-6D values. Longer 
relapses were generally associated with higher HSUVs. 
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Relapses that limited everyday activities and, in particular, relapses that resulted in a hospital 
admission were associated with large decrements in HSUVs, as compared to those who did not 
experience a relapse. For example, the difference in EQ-5D values between those who did not have a 
relapse and those who had four relapses with the last resulting in a hospital admission was 0.275. 
The equivalent figure for the SF-6D was 0.132. 
 
 
Discussion 
 
The SWIMS study provides new empirical data on the health state utility values of MS health states 
by the particular clinical features of the condition. These data provide insights into the impact of MS 
on people’s lives and the health-related quality of life of people with MS, and can be used to inform 
effectiveness and cost-effectiveness analyses of treatments for the disease.  
 
Health state utility values are presented for both the EQ-5D and the SF-6D, with the two measures 
showing a similar pattern of values associated with MS by age, gender, disease severity and clinical 
characteristics. However, there were some clear differences in the values provided by the two 
measures. There was an obvious linear decline in EQ-5D and SF-6D values by increasing disability, 
according to the EDSS. Based on previous reports which suggest a minimally important difference of 
between 0.03 (52) (53) and 0.075 (54) on the EQ-5D, the change in HSUV at each point change on 
the EDSS for ‘all diagnoses’ would be considered of clinical relevance (apart from the change from 
EDSS 3 to EDSS 4). In contrast, none of the changes in SF-6D HSUVs by point change on the EDSS 
would be considered meaningful when a minimally important difference of 0.041 is considered (55). In 
addition, the relationships between EQ-5D values and features of relapses were more pronounced 
than the relationships between SF-6D values and relapse characteristics. Stronger relationships 
between clinical characteristics and EQ-5D values than between clinical characteristics and SF-6D 
values appears to be a general pattern when comparing EQ-5D and SF-6D data in this research and 
may reflect the more compressed scale of the SF-6D (0.3 to 1, as compared to -0.594 to 1 for the EQ-
5D). This may imply a greater sensitivity of the EQ-5D to changes in varying clinical features of MS as 
compared to the SF-6D. 
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SF-6D data have not previously been reported for people with MS in the UK, and only two prior 
studies have reported SF-6D values for MS health states, in the United States (56) and Canada (57). 
Fisk et al. (57) presented data graphically, with no disaggregated detail. Noyes et al. (56) applied UK 
SF-6D values to SF-36 descriptive system data collected from people with MS in the United States 
and presented data by disease severity (EDSS). These values were consistently higher than those 
reported here (Figure 1), although this may, in part, be explained by the inclusion of people with 
PPMS in the current analysis but not in the Noyes et al. (56) data, as the SWIMS data showed lower 
SF-6D HSUVs for people with PPMS than for ‘all diagnoses’. This appears to be the first occasion 
that HSUVs for PPMS have been reported separately to other forms of MS for either the SF-6D or the 
EQ-5D (16).  
 
The pattern of SWIMS EQ-5D values by EDSS scores is broadly consistent with that of other UK 
studies (58) (22) (59) (Figure 2), although somewhat ‘flatter’, i.e. SWIMS participants have slightly 
lower EQ-5D values at less severe EDSS scores and slightly higher EQ-5D values at more severe 
EDSS scores. Findings from Parkin et al. (59) and Fogarty et al. (58) were based on small numbers of 
participants (102 and 214, respectively) as compared to the SWIMS data (1,169 EQ-5D health state 
descriptions given by 565 respondents). Results from Orme et al. (22) were based on a larger number 
of respondents (2,048), but the data were collected cross-sectionally via a patient association with a 
resulting low response rate (approximately 20%). As such, the SWIMS data may provide the least 
biased estimates of EQ-5D HSUVs. 
 
An inconsistent result previously identified by Orme et al. (22) was replicated in the SWIMS data. In 
both studies, EQ-5D values were slightly higher when individuals had an EDSS score of 4 (‘Relatively 
severe disability’), than when individuals had an EDSS score of 3 (‘Moderate disability’). This finding 
was particularly apparent for SWIMS participants with RRMS (although this was based on a relatively 
small numbers of responses). In addition, this sub-group of individuals with RRMS had higher EQ-5D 
values at EDSS score 6 (‘Assistance required to walk’), than at EDSS 5 (‘Disability precludes full daily 
activities’). These findings may reflect complexities with how clinicians use the EDSS in practice, 
limitations with its psychometric properties, particular difficulties with rating the fluctuations in disability 
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experienced by those with RRMS, the effect of patient coping strategies at the interfaces of EDSS 3/4 
and 5/6, characteristics of the EQ-5D scoring at values of approximately 0.5 to 0.6, or the result may 
have occurred randomly. The relationship between HSUVs and EDSS scores warrants further 
investigation.  
 
This is also the first time that detailed data of this type have been presented for relapses according to 
their frequency, severity and length, and considering HSUVs alongside detailed information on the 
nature of relapses has provided new insights into the impact of differing forms of relapses on the 
health-related quality of life of people with MS. For example, relapses that lasted ‘About 48 hours’ or 
‘Up to 1 week’ were associated with lower HSUVs than relapses that lasted ‘Up to 1 month’ or ‘Longer 
than 1 month’. This may imply that shorter duration relapses are more severe in terms of their impact 
on health status. However, there is no clear evidence for this in the associated literature. Alternatively, 
this result might be a manifestation of the fact that shorter duration relapses are less likely to be 
treated, for example by a course of oral or intravenous steroids and, therefore, the effects linger and 
continue to impact on health status. But this is speculative, and the true explanation may relate to the 
known complexities of defining and categorising relapses. 
 
Comparing the mean EQ-5D values of those who had experienced a relapse in the previous six 
months with those who had not experienced a relapse gave a relapse-associated decrement of 0.076. 
This was comparable with the decrement of 0.071 given by Orme et al. (22), but not with the figures of 
0.254 and 0.468 from other UK-based studies (60) (59). The potential reasons for this become 
apparent when the demographic and clinical characteristics of the participants in the latter studies are 
considered. The Forbes et al. study included only 84 participants, all of whom had SPMS. The 102 
participants in the Parkin et al. study were substantially younger than the SWIMS sample, and all had 
RRMS.  
 
The data from SWIMS provides HSUVs for individuals with RRMS, PPMS and SPMS up to 30-39 
years from diagnosis. This is a unique feature of the SWIMS dataset and such information has not 
previously been reported in this manner. The trajectory of the relationship between HSUVs and time 
since diagnosis may reflect some degree of adaptation to having MS (61). Individuals with MS may 
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view their health status as deteriorating over the first 20 to 29 years of having the disease. During this 
time they are likely to make adaptations to help live with the condition and develop psychological 
strategies for coping with the impact that it has on their lives. This process of adaptation, or 
‘normalisation’, may then be reflected at 30 to 39 years from diagnosis by individuals perceiving their 
health status to be less severely affected, thus giving improved ratings on the EQ-5D and the SF-6D 
(SF-36). This process of adaptation may happen more quickly when the disease course is more rapid, 
which could explain the earlier increases in HSUVs for people with PPMS as compared to RRMS, 
although conclusions must be tentative as numbers providing HSUV data at 30 to 39 years from 
diagnosis were small for some types of MS.  
 
The analyses reported here were limited by EDSS data not being available for all participants and not 
being reported concurrently with SWIMS data. Future research should aim to include EDSS 
assessments at the same data collection points as HSUVs. This said, problems with the EDSS, in 
both clinical and research practice (62), suggest that an alternative measure of disease progression in 
MS may be long overdue. This is supported by the inconsistent relationship between EDSS and EQ-
5D values at EDSS stages 3 and 4, and EDSS stages 5 and 6, found in this research and that of 
Orme et al. (22).  
 
This research has illuminated some of the relative merits of two of the most commonly used generic 
preference-based measures (9). Further research is now warranted to further investigate the 
psychometric functioning of the EQ-5D and the SF-6D for use in the context of MS.  
 
The SWIMS data provide opportunities for further analyses using statistical techniques, and to 
develop hypotheses regarding the associations between health state utility values and the 
demographic and clinical features of people with MS. However, given the high quality data available, 
and the apparent representativeness of SWIMS participants, descriptive statistics are given in the 
present analyses to provide the data in a simple format for use and interpretation by others. 
Regression-based analyses are a recommendation for future research. 
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The SWIMS dataset has very high response and retention rates and appears representative of the UK 
population of people with MS. As such, the current findings can be generalised to other people with 
MS. This work has demonstrated that MS has a major impact on the health-related quality of life as 
compared to population norms, especially as the disease progresses into its later stages and disability 
levels worsen. The findings also indicate the complexity of relationships between time since diagnosis 
and HSUVs, and specific features of relapses experienced and EQ-5D and SF-6D values. In addition, 
comparing the reported findings with those from previous studies has highlighted how different 
HSUVs can result based on the particular characteristics of the sample and the methodological 
approach taken. The SWIMS study has provided HSUV data based on specific clinical and 
demographic characteristics of people with MS. These can now be used to offer decision-makers 
more precise estimates of the effectiveness and cost-effectiveness of treatments for MS.  
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Table 1: Demographic and clinical characteristics of SWIMS participants at recruitment 
Characteristic  
Gender (n=1,408): n (%) 
  Male 
  Female 
 
368 (26.1%) 
1,040 (73.9%)  
Age (n=1,400): mean (sd) 
[range] years 
50.7 (11.7) 
[18.2 to 83.3] 
Type of MS (n=1,363): n (%) 
  Relapsing-Remitting 
  Primary Progressive 
  Secondary Progressive 
  Benign 
  Combination or not known* 
 
572 (42.0%) 
264 (19.4%) 
231 (17.0%) 
45 (3.3%) 
251 (18.4%) 
Time since diagnosis (n=1,347): mean (sd) 
[range] 
9.6 (10.0) 
[1 month to 53.5 years] 
EDSS score (n=289): mean (sd) 
[range] 
4.3 (2.3) 
[0 to 9] 
Experienced a relapse(s) in the previous 12 months (n=1,367): n (%) 
  Yes** 
  No 
  Don’t know 
 
732 (53.6%) 
455 (33.3%) 
180 (13.2%) 
Number of relapses in the previous 12 months (n=1,367): mean (sd) 
n (%) 
  0** 
  1 
  2 
  3 
  4 
1.1 (1.2) 
 
638 (46.7%) 
382 (27.9%) 
196 (14.3%) 
87 (6.4%) 
64 (4.7%) 
* This category refers to instances where a respondent either ticked more than one type of MS (‘benign’, 
‘relapsing-remitting’, ‘primary progressive’, ‘secondary progressive’) or ticked that they did not know which type 
they had. 
** 3 people reported that they had experienced a relapse in the previous 12 months, but in answer to an 
additional question reported that that had had zero relapses in this time frame. 
 
Table 2: HSUVs by MS type and time since diagnosis 
MS type 
Time since diagnosis 
EQ-5D SF-6D 
 n responses 
[n participants] 
Mean (sd) 
EQ-5D value 
n responses 
[n participants] 
Mean (sd) 
SF-6D value 
Relapsing-remitting: 
0 to 9 years 
10 to 19 years 
20 to 29 years 
30 to 39 years 
All 
 
745 [420] 
377 [165] 
121 [73] 
38 [20] 
1,331 [633] 
 
0.685 (0.248) 
0.666 (0.230) 
0.580 (0.292) 
0.586 (0.242) 
0.668 (0.251) 
 
671 [354] 
221 [124] 
98 [57] 
28 [16] 
1,048 [529] 
 
0.661 (0.129) 
0.659 (0.116) 
0.621 (0.116) 
0.639 (0.107) 
0.657 (0.125) 
Primary progressive: 
0 to 9 years 
10 to 19 years 
20 to 29 years 
30 to 39 years 
All 
 
281 [166] 
215 [103] 
84 [45] 
13 [10] 
617 [301] 
 
0.492 (0.294) 
0.400 (0.360) 
0.413 (0.348) 
0.378 (0.305) 
0.444 (0.330) 
 
235 [129] 
136 [77] 
70 [37] 
24 [12] 
476 [238] 
 
0.584 (0.113) 
0.574 (0.100) 
0.589 (0.108) 
0.600 (0.134) 
0.582 (0.109) 
Secondary progressive: 
0 to 9 years 
10 to 19 years 
20 to 29 years 
30 to 39 years 
All 
 
178 [105] 
247 [119] 
101 [61] 
62 [33] 
631 [301] 
 
0.450 (0.295) 
0.473 (0.290) 
0.429 (0.348) 
0.407 (0.346) 
0.450 (0.308) 
 
140 [82] 
179 [98] 
104 [56] 
27 [21] 
490 [251] 
 
0.573 (0.110) 
0.564 (0.096) 
0.560 (0.088) 
0.553 (0.096) 
0.565 (0.097) 
Benign: 
0 to 9 years 
10 to 19 years 
20 to 29 years 
30 to 39 years 
All 
 
64 [39] 
26 [18] 
16 [11] 
- 
115 [69] 
 
0.875 (0.191) 
0.815 (0.269) 
0.777 (0.250) 
- 
0.845 (0.227) 
 
46 [32] 
18 [13] 
11 [6] 
- 
99 [59] 
 
0.755 (0.121) 
0.740 (0.132) 
0.700 (0.068) 
- 
0.746 (0.117) 
All diagnoses: 
0 to 9 years 
10 to 19 years 
20 to 29 years 
30 to 39 years 
40 to 49 years 
All 
 
2,848 [842] 
1,797 [499] 
784 [230] 
297 [96] 
92 [28] 
6,066 [1,406] 
 
0.613 (0.290) 
0.533 (0.315) 
0.472 (0.332) 
0.531 (0.331) 
0.451 (0.343) 
0.566 (0.312) 
 
2,798 [788] 
1,763 [478] 
764 [223] 
305 [95] 
94 [30] 
5,964 [1,357] 
 
0.635 (0.128) 
0.610 (0.111) 
0.593 (0.111) 
0.614 (0.118) 
0.586 (0.096) 
0.620 (0.122) 
- Less than 10 observations, hence not reported. 
 
Table 3: Mean (sd) EQ-5D and SF-6D health state values by EDSS scores and disease type 
MS type n responses 
[n participants] 
Mean (sd) 
EQ-5D value 
n responses 
[n participants] 
Mean (sd) 
SF-6D value 
Relapsing-remitting: 
EDSS 0 
EDSS 1 
EDSS 2 
EDSS 3 
EDSS 4 
EDSS 5 
EDSS 6 
All 
 
21 [18] 
40 [36] 
64 [57] 
30 [27] 
25 [22] 
19 [18] 
61 [49] 
270 [194] 
 
0.897 (0.132) 
0.763 (0.186) 
0.719 (0.229) 
0.523 (0.317) 
0.596 (0.274) 
0.438 (0.359) 
0.502 (0.275) 
0.623 (0.294) 
 
21 [20] 
23 [23] 
46 [45] 
17 [17] 
-  
11 [10] 
28 [28] 
157 [133] 
 
0.701 (0.131) 
0.716 (0.144) 
0.677 (0.112) 
0.602 (0.131) 
- 
0.692 (0.135) 
0.591 (0.085) 
0.657 (0.128) 
Primary progressive: 
EDSS 3 
EDSS 4 
EDSS 5 
EDSS 6 
EDSS 7 
EDSS 8 
EDSS 9 
All 
 
10 [9] 
- 
10 [10] 
42 [36] 
18 [15] 
17 [16] 
- 
107 [90] 
 
0.595 (0.251) 
- 
0.525 (0.259) 
0.500 (0.254) 
0.365 (0.281) 
-0.067 (0.198) 
- 
0.393 (0.349) 
 
- 
- 
- 
32 [26] 
- 
- 
- 
64 [53] 
 
- 
- 
- 
0.553 (0.092) 
- 
- 
- 
0.580 (0.104) 
Secondary progressive: 
EDSS 6 
EDSS 7 
EDSS 8 
EDSS 9 
All 
 
81 [58] 
12 [11] 
16 [14] 
- 
125 [92] 
 
0.481 (0.269) 
0.397 (0.317) 
0.021 (0.387) 
- 
0.421 (0.334) 
 
50 [37] 
11 [10] 
- 
- 
79 [61] 
 
0.569 (0.094) 
0.517 (0.127) 
- 
- 
0.570 (0.100) 
All diagnoses*: 
EDSS 0 
EDSS 1 
EDSS 2 
EDSS 3 
EDSS 4 
EDSS 5 
EDSS 6 
EDSS 7 
EDSS 8 
EDSS 9 
All 
 
48 [35] 
78 [60] 
135 [109] 
91 [79] 
86 [65] 
86 [67] 
494 [258] 
76 [55] 
69 [44] 
- 
1,169 [565] 
 
0.846 (0.182) 
0.762 (0.220) 
0.711 (0.221) 
0.608 (0.281) 
0.609 (0.256) 
0.531 (0.286) 
0.496 (0.269) 
0.392 (0.278) 
0.025 (0.314) 
- 
0.535 (0.317) 
 
46 [35] 
56 [49] 
119 [105] 
94 [72] 
70 [55] 
73 [55] 
425 [234] 
73 [57] 
62 [41] 
- 
1,026 [529] 
 
0.702(0.124) 
0.691 (0.132) 
0.669 (0.121) 
0.646 (0.117) 
0.635 (0.096) 
0.610 (0.104) 
0.581 (0.090) 
0.554 (0.103) 
0.529 (0.111) 
- 
0.609 (0.115) 
* ‘All diagnoses’ include responses where participants did not report their MS type. 
- Less than 10 observations, hence not reported. 
 
Table 4: HSUVs by features of relapses experienced in previous six months 
 EQ-5D SF-6D 
 n responses 
[n participants] 
Mean (sd) EQ-
5D value 
n responses 
[n participants] 
Mean (sd) 
SF-6D value 
No relapse in past 6 months 
>1 relapse in past 6 months 
2,872 [989] 
2,131 [952] 
0.610 (0.303) 
0.534 (0.316) 
2,902 [978] 
1,990 [880] 
0.649 (0.124) 
0.597 (0.115) 
Relapse frequency: 
1 relapse 
2 relapses 
3 relapses 
4 relapses 
No. of relapses not reported 
 
1,281 [720] 
531 [391] 
177 [146] 
125 [103] 
17 [16] 
 
0.570 (0.297) 
0.504 (0.316) 
0.469 (0.352) 
0.380 (0.377) 
- 
 
1,242 [700] 
486 [325] 
149 [127] 
102 [83] 
1 [11] 
 
0.607 (0.115) 
0.588 (0.110) 
0.571 (0.117) 
0.551 (0.115) 
- 
Relapse duration: 
1st relapse 
Lasted about 48 hours 
Lasted up to 1 week 
Lasted up to 1 month 
Lasted longer than 1 month 
2nd relapse 
Lasted about 48 hours 
Lasted up to 1 week 
Lasted up to 1 month 
Lasted longer than 1 month 
3rd relapse 
Lasted about 48 hours 
Lasted up to 1 week 
Lasted up to 1 month 
Lasted longer than 1 month 
4th relapse 
Lasted about 48 hours 
Lasted up to 1 week 
Lasted up to 1 month 
Lasted longer than 1 month 
 
 
125 [100] 
363 [255] 
400 [308] 
439 [328] 
 
78 [68] 
158 [116] 
120 [109] 
97 [85] 
 
32 [26] 
50 [42] 
32 [30] 
25 [24] 
 
16 [13]  
10 [10] 
- 
44 [40] 
 
 
0.558 (0.322) 
0.544 (0.304) 
0.606 (0.278) 
0.589 (0.300) 
 
0.457 (0.347) 
0.497 (0.315) 
0.558 (0.266) 
0.610 (0.274) 
 
0.440 (0.345) 
0.537 (0.299) 
0.619 (0.256) 
0.428 (0.375) 
 
0.448 (0.395) 
0.396 (0.399) 
- 
0.382 (0.403) 
 
 
128 [128] 
324 [234] 
413 [289] 
390 [288] 
 
70 [53] 
152 [115] 
110 [92] 
85 [75] 
 
28 [24] 
48 [40] 
22 [20] 
16 [16] 
 
16 [15] 
13 [13] 
- 
29 [26] 
 
 
0.597 (0.115) 
0.608 (0.114) 
0.610 (0.114) 
0.618 (0.118) 
 
0.598 (0.104) 
0.589 (0.113) 
0.598 (0.116) 
0.611 (0.113) 
 
0.579 (0.128) 
0.567 (0.118) 
0.607 (0.108) 
0.575 (0.145) 
 
0.580 (0.146) 
0.586 (0.109) 
- 
0.529 (0.114) 
Relapse severity: 
1st relapse 
Limited everyday activities 
Hospital admission 
2nd relapse 
Limited everyday activities 
Hospital admission 
3rd relapse 
Limited everyday activities 
Hospital admission 
4th relapse 
Limited everyday activities 
Hospital admission 
 
 
1,731 [820] 
184 [158] 
 
610 [390] 
41 [40] 
 
195 [151] 
15 [15] 
 
69 [64] 
- 
 
 
0.510 (0.312) 
0.484 (0.326) 
 
0.474 (0.321) 
0.453 (0.359) 
 
0.439 (0.341) 
0.335 (0.329) 
 
0.380 (0.378) 
- 
 
 
1,605 [770] 
166 [142] 
 
536 [332] 
33 [31] 
 
162 [127] 
14 [14] 
 
55 [47] 
- 
 
 
0.582 (0.106) 
0.573 (0.118) 
 
0.561 (0.098) 
0.568 (0.125) 
 
0.541 (0.100) 
0.517 (0.083) 
 
0.508 (0.082) 
- 
- Less than 10 observations, hence not reported. 
 
Figure 1: SF-6D values for SWIMS participants and people with MS in the Noyes et al (2011) study 
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Figure 2: EQ-5D values for SWIMS participants and other comparable studies of people with MS 
 
0 1 2 3 4 5 6 7 8
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Supplement 1 
 
Tables 1A and 2A present health state utility values for MS by age and gender, alongside 
comparative data from representative samples of the UK general population (1) (2) (3). These data 
demonstrate the negative impact of MS on people’s health-related quality of life as measured by both 
the EQ-5D and the SF-6D. For example, Table 1A reports a difference of 0.3 in EQ-5D HSUVs 
between those with MS and the general population and Table 2A reports such a difference of 0.17 in 
SF-6D health state values.  
 
Table 1A: EQ-5D HSUVs for people with MS by age and gender, compared to a representative 
sample of UK population  
 All Male Female 
Age 
(years) 
UK 
population 
mean (sd) 
n* 
People with 
MS 
mean (sd) 
n responses 
UK 
population 
mean (sd) 
n* 
People with 
MS 
mean (sd) 
n responses 
UK 
population 
mean (sd) 
n* 
People with 
MS 
mean (sd) 
n responses 
All ages 0.86 (0.23) 
3,392 
0.56 (0.31) 
6,066 
0.86 (0.24) 
1,467 
0.54 (0.32) 
1,407 
0.85 (0.22) 
1,925 
0.57 (0.31) 
4,656 
< 25 0.94 (0.12) 
304 
0.71 (0.29) 
77 
0.94 (0.12) 
128 
- 0.94 (0.12) 
176 
0.69 (0.30) 
69 
25 to 34 0.93 (0.15) 
753 
0.68 (0.30) 
472 
0.93 (0.16) 
330 
0.68 (0.30) 
84 
0.93 (0.15) 
423 
0.68 (0.30) 
388 
35 to 44 0.91 (0.16) 
561 
0.63 (0.29) 
1,385 
0.91 (0.17) 
256 
0.58 (0.31) 
304 
0.91 (0.15) 
305 
0.64 (0.28) 
1,081 
45 to 54 0.85 (0.25) 
488 
0.55 (0.31) 
1,771 
0.84 (0.27) 
221 
0.50 (0.32) 
438 
0.85 (0.23) 
267 
0.56 (0.30) 
1,333 
55 to 64 0.80 (0.26) 
484 
0.51 (0.32) 
1,725 
0.78 (0.28) 
196 
0.50 (0.33) 
427 
0.81 (0.26) 
288 
0.51 (0.32) 
1,298 
65 to 74 0.78 (0.26) 
488 
0.50 (0.29) 
545 
0.78 (0.28) 
228 
0.54 (0.28) 
118 
0.78 (0.25) 
260 
0.49 (0.29) 
427 
75+ 0.73 (0.27) 
314 
0.38 (0.36) 
62 
0.78 (0.25) 
108 
0.51 (0.31) 
16 
0.71 (0.27) 
206 
0.34 (0.36) 
46 
- Less than 10 observations, hence not reported. 
*Source: Kind, Hardman (1), Table A. 
 
 
  
Table 2A: SF-6D HSUVs for people with MS by age and gender, compared to a representative 
sample of UK population 
 All Male Female 
Age 
(years) 
UK population 
mean (sd)* 
n* 
People with 
MS 
mean (sd) 
n 
responses 
UK population 
mean (sd)* 
n* 
People with 
MS 
mean (sd)* 
n 
responses 
UK 
population 
mean (sd)* 
n* 
People with 
MS 
mean (sd) 
n responses 
All 
ages 
0.79 (0.15) 
22,166 
0.62 (0.12) 
5,964 
0.81 (0.15) 
9,664 
0.61 (0.12) 
1,392 
0.79 (0.11) 
12,502 
0.62 (0.12) 
4,565 
20 to 
24 
0.82 (0.14) 
1,441 
0.73 (0.15) 
25 
0.83 (0.18) 
628 
- 0.80 (0.12) 
813 
 0.69 (0.15) 
19  
25 to 
29 
0.82 (0.13) 
1,729 
0.71 (0.14) 
84 
0.83 (0.13) 
754 
0.72 (0.13) 
11 
0.81 (0.11) 
975 
0.70 (0.14) 
73 
30 to 
34 
0.81 (0.13) 
1,795 
0.67 (0.15) 
216 
0.83 (0.11) 
783 
0.66 (0.17) 
30 
0.80 (0.13) 
1,013 
0.67 (0.14) 
186 
35 to 
39 
0.81 (0.14) 
2,061 
0.65 (0.13) 
396 
0.83 (0.17) 
899 
0.63 (0.13) 
91 
0.80 (0.14) 
1,163 
0.66 (0.13) 
305 
40 to 
44 
0.81 (0.14) 
2,172 
0.64 (0.13) 
701 
0.82 (0.14) 
947 
0.62 (0.11) 
146 
0.79 (0.14) 
1,225 
0.65 (0.13) 
555 
45 to 
49 
0.79 (0.14) 
1,995 
0.63 (0.12) 
876 
0.81 (0.15) 
870 
0.61 (0.11) 
193 
0.78 (0.14) 
1,125 
0.63 (0.12) 
683 
50 to 
54 
0.79 (0.15) 
1,818 
0.62 (0.12) 
888 
0.79 (0.16) 
792 
0.60 (0.11) 
217 
0.79 (0.15) 
1,025 
0.62 (0.13) 
671 
55 to 
59 
0.78 (0.17) 
1,707 
0.61 (0.11) 
878 
0.80 (0.15) 
744 
0.60 (0.11) 
207 
0.76 (0.16) 
963 
0.61 (0.11) 
671 
60 to 
64 
0.78 (0.15) 
1,795 
0.60 (0.11) 
861 
0.78 (0.16) 
783 
0.59 (0.10) 
214 
0.77 (0.16) 
1,013 
0.61 (0.11) 
647 
65 to 
69 
0.78 (0.14) 
1,441 
0.60 (0.11) 
622 
0.80 (0.15) 
628 
0.60 (0.11) 
178 
0.76 (0.16) 
813 
0.60 (0.11) 
444 
70 to 
74 
0.76 (0.16) 
1,153 
0.58 (0.10) 
258 
0.77 (0.15) 
503 
0.58 (0.11) 
55 
0.75 (0.16) 
650 
0.58 (0.10) 
203 
75 to 
79 
0.73 (0.16) 
687 
0.60 (0.12) 
90 
0.76 (0.16) 
300 
0.57 (0.10) 
20 
0.71 (0.15) 
388 
0.61 (0.12) 
70 
80 to 
84 
0.70 (0.15) 
576 
0.57 (0.11) 
21 
0.74 (0.15) 
251 
- 0.68 (0.14) 
325 
0.57 (0.11) 
14 
85+ 0.66 (0.14) 
377 
0.59 (0.09) 
40 
0.70 (0.16) 
164 
0.59 (0.09) 
14 
0.64 (0.13) 
213 
0.56 (0.08) 
19 
- Less than 10 observations, hence not reported. 
* Estimated from data given by van der Berg (3), p.1510. 
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